DJ BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023 BILENDI BILENDI: Results for the 2023 financial year: marked improvement in profitability
DJ BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023
-- In France, following three consecutive quarters of growth, revenues increased by +5.2% to EUR14.1m.In the second half of 2023, EBITDA rose by +2.9% to EUR7.8m, giving an EBITDA margin of 23.5%, benefiting from the combined effect of a sharper increase in business and the management of operating costs over the period. This rate of growth will be stable on a like-for-like basis in 2024 and will be +11.2 points higher sequentially than in the first half of 2023.
Thanks to good momentum for the year ahead and although it is advisable to remain cautious given the ongoing macro-economic uncertainties, Bilendi is relatively confident in its ability to continue to generate growth accompanied by sustained profitability in 2024. Other major innovations will also be announced over the course of the year to continue revolutionising the market research sector.Bilendi is reaffirming its aggressive growth strategy combining development and targeted acquisitions with the aim of achieving sales of EUR100m by 2026, and EBITDA of 20% to 25% of sales, i.e., EUR20m to EUR25m.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
BioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdateAdvanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and
Read more »
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business UpdateConference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN, MA / ACCESSWIRE / March 15, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the 'Company'), a biopharmaceutical company specializing
Read more »
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update(This release corrects the release that was posted earlier on March 15, 2024 to update the Consolidated Balance Sheets)Conference call begins at 10:00 a.m. Eastern time on Monday, March 18, 2024WOBURN
Read more »
Ainos, Inc.: Ainos Reports Full Year 2023 Financial ResultsStrategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024Advancing VELDONA drug candidates to Phase III clinical studiesExpanding market of AI Nose-powered VOC-sensing technology
Read more »
Grupo Clarín S.A.: Grupo Clarín Announces Full Year and Last Quarter 2023 ResultsBUENOS AIRES, ARGENTINA / ACCESSWIRE / March 8, 2024 / Grupo Clarín S.A. ('Grupo Clarín' or the 'Company') (LSE:GCLA)(BCBA:GCLA), the largest media company in Argentina, announced today its Full Year and
Read more »